A Phase 4 interventional study of Brainsway H4 deep rTMS coil and Brainsway stimulator system in Smoking, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Centre for Addiction and Mental Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Smoking by Centre for Addiction and Mental Health — 2 open to participants now, 2 under way, none of them phase 3. Smoking · Centre for Addiction and Mental Health.
Among the 16 studies in Smoking by Centre for Addiction and Mental Health, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2024, is one of 5 in phase 4, and was the 15th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →2 of the 16 studies in Smoking by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–85
By country, each count listing its studies:
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 58 across the 15 interventional studies, 26 across the 1 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
1 of the studies in Smoking by Centre for Addiction and Mental Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06346028Centre for Addiction and Mental HealthImplementation of Transcranial Magnetic Stimulation for Smoking Cessation | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Smoking by Centre for Addiction and Mental Health, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Repetitive transcranial magnetic stimulation (rTMS) is an alternative non-invasive treatment to help people quit smoking. rTMS uses a magnetic field to stimulate regions of the brain that are involved in addiction. The two brain regions that are stimulated are the insula and the dorsolateral prefrontal cortex, which are involved in drug craving and decision-making, respectively.
The goal of this clinical trial is to learn more about the feasibility of offering rTMS as a treatment in the Nicotine Dependence Clinic (NDC) to help daily smokers to quit smoking. The NDC is at the Center for Addiction and Mental Health (CAMH) at 1025 Queen Street West, in Toronto, Canada.
Participants will be asked to come to CAMH to:
Objectives
Approximately 45,000 Canadians die from smoking each year and smoking is the leading preventable cause of death worldwide. Quitting smoking is difficult, and current treatments such as varenicline and nicotine replacement therapy are not always able to help people quit.
Repetitive transcranial magnetic stimulation (rTMS) is an alternative non-invasive treatment to help people quit smoking. rTMS uses a magnetic field to stimulate regions of the brain that are involved in addiction. The two brain regions that are stimulated are the insula and the dorsolateral prefrontal cortex, which are involved in drug craving and decision-making, respectively.
A landmark 2021 study showed that daily rTMS treatment for 6 weeks targeting these regions is effective at reducing craving and cigarette use. This study's findings provided supporting evidence that led Health Canada and the Food and Drug Administration to approve rTMS as a treatment for smoking cessation. Currently, this treatment is not widely available, therefore it is important to learn more about how to bring it into clinics and develop it further.
The goal of this clinical trial is to learn more about the feasibility of offering rTMS as a treatment in the Nicotine Dependence Clinic (NDC) to help daily smokers to quit smoking. The NDC is at the Center for Addiction and Mental Health (CAMH) at 1025 Queen Street West, in Toronto, Canada.
The main questions it aims to answer are:
Participants will be asked to come to CAMH to:
Objectives
Inclusion Criteria: Patients receiving rTMS
Inclusion Criteria: Health care providers
Exclusion Criteria: Patients receiving rTMS
Exclusion Criteria: Health care providers
- There are no exclusion criteria for HCP Participants
Participants will receive 3 weeks of daily (Monday to Friday) rTMS sessions followed by 3 weeks of weekly rTMS sessions for a total of 6 weeks of treatment. Each session lasts about 25 minutes and is provided by an rTMS technician at the Temerty Center at 1025 Queen Street West, with medical supervision.
Device: Brainsway H4 deep rTMS coil and Brainsway stimulator system
An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks. Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time. At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start. Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC.
Also known as: Deep rTMS
The primary objective of the study is to evaluate the feasibility of implementing rTMS in the Nicotine Dependence Clinic (NDC) at CAMH, in Toronto. This is determine by reach, the extent to which patients are engaging in the rTMS treatment.
The proportion of patients accepting rTMS relative to all patients with a visit to the NDC during the study period.
Time frame: Through study completion, an average of 1 year
Identify rates of adoption of rTMS in Nicotine Dependence Clinic
What percentage of NDC HCPs refer patients to rTMS treatment? (Adoption)
Time frame: Through study completion, an average of 1 year
Identify contextual determinants of rTMS adoption and reach NDC through a qualitative approach.
Research questions assessed through through surveys and semi-structured interviews 1. What are the multi-level barriers and facilitators to integrating rTMS in NDC? 2. How acceptable, appropriate and feasible is it to integrate rTMS in NDC?
Time frame: Through study completion, an average of 1 year
Evaluate the effectiveness of rTMS on smoking cessation rates in real world patients with common comorbidities seeking treatment at NDC.
Self-reported 4-week continuous quit rate and long follow-up continuous quit rate (biochemically verified by urine nicotine/tobacco metabolite collection and analysis at end of treatment and the long follow-up).
Time frame: Through study completion, an average of 1 year
Explore patient-HCP communication about shared treatment decision-making for rTMS.
We will conduct semi-structured interviews with NDC patients and HCPs to better understand the collaborative nature and necessary communication components involved in shared treatment decision-making for rTMS.
Time frame: Through study completion, an average of 1 year
Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 39 months after the start.
Of 29 non-industry phase 4 interventional studies under Smoking, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 39 months is above that.
Counting every sponsor, half of 29 studies reached it within 35 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre for Addiction and Mental Health →